Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-06-26 10:10 (1149 d 23:46 ago) – Posting: # 20361
Views: 2,246

Hi NK,

» The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"
» As per my understanding, Dihydroergotamine is neither endogenous …

Correct.

» … nor available in the diet, …

Oh yes! Even when, it would practically not absorbed.

» … then why baseline value is required?

IMHO, a bizarre idea. Ask the FDA.

» If it is required, …

It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

» … what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

The FDA’s general approach for a stable baseline is subtracting the mean of {-1 h, -0.5 h, pre-dose}. In your case likely it would be BQL anyhow. ;-)

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 14 (0 registered, 14 guests [including 2 identified bots]).
Forum time: Friday 09:57 CEST (Europe/Vienna)

Doctors are men who prescribe medicines of which they know little,
to cure diseases of which they know less,
in human beings of whom they know nothing.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5